

CICbioGUNE



MEMBER OF BASQUE RESEARCH
& TECHNOLOGY ALLIANCE

Activity Report 2025




Table of Contents

..... About us	2
..... 2025 in Numbers	5
..... Funding	7
..... Awarded Applications	8
..... Publications	9
..... PhD Thesis	9
..... Innovation, IP, Economic Activity & Research Contracts	10
..... Scientific Seminars	11
..... Local,National & International Visibility	12
..... Scientific Education & Citizen Participation	14
..... Press, Social Media & Web	14
..... Research	15
..... Projects & Funding Applications	25
..... Innovation	38
..... Personnel,Talent & Awards	43
..... Scientific Communication & Outreach	44
..... Equality Plan	46



CIC bioGUNE conducts pioneering **multidisciplinary research** at the intersection of Chemistry, Data Science, Biology, and Biomedicine. Our mission is to advance **Precision & Personalized Medicine** by exploring the molecular mechanisms of diseases. CIC bioGUNE researchers focus on Structural, Molecular, Cell Biology, and Immunology tools with the aim of **developing more targeted and effective treatments**.







60%

Published in D1 Scientific Magazines



20.2 M€

Budget



20

Research Groups

ALL NUMBERS

In 2025, **CIC bioGUNE consolidated its position as a leading European biomedical research center** through outstanding performance across competitive funding, scientific excellence, talent recruitment, innovation, and international visibility. The year was marked by strong growth in both scientific output and translational impact, reinforcing the center's strategic role in life sciences and biomedicine.

CIC bioGUNE sustained a **broad and ambitious research portfolio addressing major biomedical challenges**, including cancer, gene editing technologies, metabolic diseases, infectious diseases, and neurobiology.

The center celebrated its **20th Anniversary**, marking two decades of scientific excellence and institutional growth.

Strategic collaborations were strengthened, notably the CIMA–CIC bioGUNE alliance, which integrates research and innovation efforts in gene editing, viral vectors, and advanced therapies, positioning it as a key translational partnership.

In addition, CIC bioGUNE **expanded its international networks**, including participation in initiatives such as GlycoNet, and reinforced societal engagement through collaborations linking biomedical research with sport and health, including partnerships with Athletic Club.

Scientific dissemination, communication and outreach were reinforced through an **active seminar program featuring world-leading institutions** such as MIT, Harvard, and Max Planck, as well as initiatives like the **ERC FRONTIERS Science Journalism Residency**.

These activities, together with high-level scientific events, diplomacy initiatives, and outreach programs, significantly enhanced the center's global visibility and impact.

Personnel

234



Staff 2025-12-31

232.0

FTE (2025)

113.7

Permanent Staff



176

Subscribers



20



Research Group





6

Technology Platforms

Personnel



Funding



Awarded Applications



49

Awarded Applications



23%

Basque Country

11 Awarded Applications

7

Research Projects

3

Human Capital

1

Structural Funding



67%

Spain

33 Awarded Applications

21

Research Projects

12

Human Capital



10%

Other International

6 Awarded Applications

3

Research Projects
(Europe)

3

Research Projects
(International)

Publications

87%


Q1

60%

D1

124

H-INDEX



PhD Thesis

90


In progress

2

International

2

Industrial




7
Invention Disclosures
(IDF) Registered

6
New Patent
Families Filed

22
Patents
Filed

85
Active
Patents

13
New Research
Contracts





Ivan Cárcamo-Orive

*Biobizkaia Health
Research Institute, ES*



Mariana Medina

CIC nanoGUNE, ES



Ruairi Mackenzie

*Freelance Science
Journalist, SCO*



Francisco J. Planes

*Universidad de
Navarra, ES*



Guillermo Abascal

*Biofisika Institute (CSIC,
UPV/EHU), ES*



Pamina Winkler

University of Vienna, AT



Sonia Vallabh

*Broad Institute of MIT &
Harvard, US*



Laia Querol

Radboudumc, NL



Amaia Carrión

*Basque Center on
Cognition, Brain and
Language, ES*



Antonio Zorzano

IRB Barcelona, ES



Nuria Alegret

Biopuzkoa, ES



Noemí Jiménez-Rojo

*Department of
Biochemistry (EHU), ES*



Natalia Baranova

CIC biomaGUNE, ES



Lara Mahal

University of Alberta, CA



Antonio Molinaro

*Università degli Studi di
Napoli Federico II, IT*



Clara García

POLYMAT, ES



Laia Pellejà

I-CERCA, ES



Beatriz Navarro

Innarima, ES



Rubén Nogueiras

CIMUS, ES



Amaia Arruabarrena

*Departamento de
Genética, Antropología
Física y Fisiología
Animal (EHU), ES*



Malte Gersch

*Max Planck Institute of
Molecular Physiology,
GE*



Josep Rizo-Rey

*University of Texas
Southwestern Medical
Center at Dallas, US*



Fernando J. Corrales

*National Center for
Biotechnology CSIC, ES*



Christoph Müller

*Biozentrum, University
of Basel, CH*



Guillermo Luxán

*Goethe University
Frankfurt, GE*



Ana Gimeno

CIC bioGUNE, ES



Miquel Durán

*Ersilia Open Source
Initiative, ES*



Irene Marco

*Institute of
Bioengineering of
Catalonia (IBEC), ES*



Olga Barca

CIMUS, ES



Therese Sørli

*Oslo University Hospital
Research, NO*



**Raúl Pérez-
Jiménez**

CIC bioGUNE, ES



**Joseph
Schacherer**

*University of
Strasbourg, FR*



Barbara Imperiali

*Massachusetts Institute
of Technology (MIT), US*



Mika Ala-Korpela

University of Oulu, FI



René Bernards

*Netherlands Cancer
Institute (NKI), NL*



Ana Ruiz-Sáenz

CIC bioGUNE, ES

Local, National & International Visibility

Cic bioGUNE´s 20th anniversary



ERC Science Journalism Residency Program focused on Rare Diseases



FRONTIERS
science journalism initiative

Óscar Millet, appointed Vice President of Groupement AMPERE, the leading European organization in Nuclear Magnetic Resonance



International Partnership with GlycoNet (Canadian Glycomics Network) to Advance Global Glycomics Research



Participation in the Scientific Diplomacy Conference in Brno (Czech Republic)



Strategic Scientific Collaboration with Athletic Club



40th Biennial Meeting of the Royal Spanish Society of Chemistry (RSEQ)



20th International Congress of ASEICA



VIII Glycobasque Meeting



Scientific Education & Citizen Participation



32 k
People Reached by
Citizen Participation Actions



51
Total Outreach Activities



26
Center's Visits

49%



In-person

51%



Online



Press, Social Media & Web



184
Media impact

- 104 Online
- 51 Press
- 20 Radio
- 9 TV



37 k



13 k



932



832



1.13 k



506

Followers on Social Media

199 k - Web Visits



128 k - Website Users

Research



160

Scientific Publications

HIGHLIGHTED ARTICLES

HIGHLIGHTED REVIEWS



14

Participation in Editorial & Advisory Boards of Journals

EDITORIAL & ADVISORY BOARDS



17

Defended Thesis

COVERS

Throughout 2025, scientific production remained at a high level of excellence, with **87% of publications in Q1** journals and **60% in D1** journals, and an h-index of 124. Research activity spanned major areas such as cancer biology and immunology, liver disease, glycobiology, proteogenomics, computational chemistry, microbiota, and AI-driven biomedical research. The **overall portfolio** reflects a strong emphasis on **translational oncology, systems biology, and data-driven approaches to complex diseases**.

The institute maintained a strong training environment with approximately **90 PhD students in progress** and **17 doctoral theses defended**, including **international and industrial doctorates**.


Highlighted Articles



Evolutionary convergence of sensory circuits in the pallium of amniotes.

Rueda-Alaña E, Senovilla-Ganzo R, Grillo M, Vázquez E, Marco-Salas S, Gallego-Flores T, Ordeñana-Manso A, Ftara A, Escobar L, Benguría A, Quintas A, Dopazo A, Rábano M, Vivanco MD, Aransay AM, Garrigos D, Toval Á, Ferrán JL, Nilsson M, Encinas-Pérez JM, De Pittà M, García-Moreno F. Science. 2025 Jan 2;387(6735):eadp3411. doi: 10.1126/science.adp3411. Epub 2025 Feb 14. PMID: 39946453.

Cancer Heterogeneity Lab & Genome Analysis Platform




Precision proteogenomics reveals pan-cancer impact of germline variants.

Martins Rodrigues F, Terekhanova NV, Imbach KJ, Clauser KR, Esai Selvan M, Mendizabal I, Geffen Y, Akiyama Y, Maynard M, Yaron TM, Li Y, Cao S, Storrs EP, Gonda OS, Gaite-Reguero A, Govindan A, Kawaler EA, Wyczalkowski MA, Klein RJ, Turhan B, Krug K, Mani DR, Leprevost FDV, Nesvizhskii AI, Carr SA, Fenyö D, Gillette MA, Colaprico A, Iavarone A, Robles AI, Huang KL, Kumar-Sinha C, Aguet F, Lazar AJ, Cantley LC, Marigorta UM, Gümüş ZH, Bailey MH, Getz G, Porta-Pardo E, Ding L; Clinical Proteomic Tumor Analysis Consortium. Cell. 2025 May 1;188(9):2312-2335.e26. doi: 10.1016/j.cell.2025.03.026. Epub 2025 Apr 14. PMID: 40233739; PMCID: PMC12326532. *Integrative Genomics Lab.*



A resurrected ancestor of Cas12a expands target access and substrate recognition for nucleic acid editing and detection.

Jabalera Y, Tascón I, Samperio S, López-Alonso JP, Gonzalez-Lopez M, Aransay AM, Abascal-Palacios G, Beisel CL, Ubarretxena-Belandia I, Perez-Jimenez R. Nat Biotechnol. 2025 Oct;43(10):1663-1672. doi: 10.1038/s41587-024-02461-3. Epub 2024 Oct 31. PMID: 39482449. [Synthetic Biology Lab & Genome Analysis Platform](#)




Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates.

Córdoba KM, Jericó D, Jiang L, Collantes M, Alegre M, García-Ruiz L, Manzanilla O, Sampedro A, Herranz JM, Insausti I, Martinez de la Cuesta A, Urigo F, Alcaide P, Morán M, Martín MA, Lanciego JL, Lefebvre T, Gouya L, Quincoces G, Unzu C, Hervas-Stubbs S, Falcón-Pérez JM, Alegre E, Aldaz A, Fernández-Seara MA, Peñuelas I, Berraondo P, Martini PGV, Avila MA, Fontanellas. Gut. 2025 Jan 17;74(2):270-283. doi: 10.1136/gutjnl-2024-332619. PMID: 39366725; PMCID: PMC11874285. [Exosomes Lab](#)



Controlling Glycan Folding with Ionic Functional Groups.

Yadav N, Poveda A, Vázquez Mena Y, Rosenthal M, Ogawa Y, Jiménez-Barbero J, Delbianco M.. J Am Chem Soc. 2025 May 7;147(18):15126-15135. doi: 10.1021/jacs.4c17992. Epub 2025 Apr 24. PMID: 40273339; PMCID: PMC12063165. [Chemical Glycobiology Lab](#)




TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells.

Priego N, de Pablos-Aragonese A, Perea-García M, Pieri V, Hernández-Oliver C, Álvaro-Espinosa L, Rojas A, Sánchez O, Steindl A, Caleiras E, García F, García-Martín S, Graña-Castro O, García-Mulero S, Serrano D, Velasco-Beltrán P, Jiménez-Lasheras B, Egia-Mendikute L, Rupp L, Stammberger A, Meinhardt M, Chaachou-Charradi A, Martínez-Saez E, Bertero L, Cassoni P, Mangherini L, Pellerino A, Rudà R, Soffietti R, Al-Shahrour F, Saftig P, Sanz-Pamplona R, Schmitz M, Crocker SJ, Calvo A, Palazón A; RENACER; Valiente M. Cancer Discov. 2025 Jan 13;15(1):179-201. doi: 10.1158/2159-8290.CD-24-0134. PMID: 39354883; PMCID: PMC11726018. [Cancer Immunology & Immunotherapy lab](#)



Long, Synthetic Staphylococcus aureus Type 8 Capsular Oligosaccharides Reveal Structural Epitopes for Effective Immune Recognition.


Østerlid KE, Sorieul C, Unione L, Li S, García-Sepúlveda C, Carboni F, Del Bino L, Berni F, Arda A, Overkleeft HS, van der Marel GA, Romano MR, Jiménez-Barbero J, Adamo R, Codée JDC. Longl Am Chem Soc. 2025 Jan 22;147(3):2829-2840. doi: 10.1021/jacs.4c16118. Epub 2025 Jan 10. PMID: 39792791; PMCID: PMC11760181. [Chemical Glycobiology Lab](#)



Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.

Elurbide J, Colyn L, Latasa MU, Uriarte I, Mariani S, Lopez-Pascual A, Valbuena E, Castello-Urbe B, Arnes-Benito R, Adan-Villaescusa E, Martinez-Perez LA, Azkargorta M, Elortza F, Wu H, Krawczyk M, Schneider KM, Sangro B, Aldrighetti L, Ratti F, Casadei Gardini A, Marin JJG, Amat I, Urman JM, Arechederra M, Martinez-Chantar ML, Trautwein C, Huch M, Cubero FJ, Berasain C, G Fernandez-Barrena M, Avila MA. Gut. 2024 Dec 19;74(1):116-127. doi: 10.1136/gutjnl-2024-332998. PMID: 39266051; PMCID: PMC12056590.


Liver Disease Lab & Proteomics Platform



Electrostatic atlas of non-covalent interactions built into metal-organic frameworks.

frameworks Ji Z, Mukherjee S, Andreo J, Sinelshchikova A, Peccati F, Jiménez-Osés G, Wuttke S, Boxer SG. Nat Chem. 2025 Dec;17(12):1920-1927. doi: 10.1038/s41557-025-01916-7. Epub 2025 Aug 27. PMID: 40866609; PMCID: PMC12473737.

Computational Chemistry Lab



E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.

Apodaka-Biguri M, Simão AL, González-Romero F, Mestre D, Rodrigues PM, Aurrekoetxea I, Gómez-Santos B, Buqué X, Nieva-Zuluaga A, de Gauna MR, Fernandez-Puertas I, Gomez-Jauregui P, Sainz-Ramirez N, Alfaro-Jiménez K, Ortiz-Palma A, Castellero E, Iglesias-Ara A, Mitxelena J, Eriz A, Aransay AM, Lozano JJ, Marin JJG, Izquierdo-Sanchez L, Perugorria MJ, Bujanda L, Banales JM, Martín C, Mosteiro L, Errazti G, Syn WK, Castaño L, Zubiaga AM, Castro RE, Aspichueta P. E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p. Hepatology. 2025 Jul 28. doi: 10.1097/HEP.0000000000001461. Epub ahead of print. PMID: 40720724. *Genome Analysis Platform*




Preclinical Protein Signatures of Crohn's Disease and Ulcerative Colitis: A Nested Case-Control Study Within Large Population-Based Cohorts.

Grännö O, Bergemalm D, Salomon B, Lindqvist CM, Hedin CRH, Carlson M, Dannenberg K, Andersson E, Keita ÅV, Magnusson MK, Eriksson C, Lanka V; BIOIBD consortium; Magnusson PKE, D'Amato M, Öhman L, Söderholm JD, Hultdin J, Kruse R, Cao Y, Repsilber D, Grip O, Karling P, Halfvarson J. Gastroenterology. 2025 Apr;168(4):741-753. doi: 10.1053/j.gastro.2024.11.006. Epub 2024 Nov 26. PMID: 39608683. *Gastrointestinal Genetics Lab*



KLRG1 identifies regulatory T cells with mitochondrial alterations that accumulate with aging.

Soto-Herederó G, Gabandé-Rodríguez E, Carrasco E, Escrig-Larena JI, Gómez de Las Heras MM, Delgado-Pulido S, Francos-Quijorna I, Blanco EM, Fernández-Almeida Á, Abia D, Rodríguez MJ, Fernández-Díaz CM, Álvarez-Flores MB, Ramírez de Molina A, Jung S, Del Sol A, Zorita V, Sánchez-Cabo F, Torroja C, Mittelbrunn M. Nat Aging. 2025 May;5(5):799-815. doi: 10.1038/s43587-025-00855-9. Epub 2025 Apr 30. PMID: 40307497; PMCID: PMC12092250. *Computational Biology Lab*



Rational Crystal Contact Engineering for Programmable Self-Assembled Protein Architectures.

Liutkus M, Rojas AL, Cortajarena AL. Angew Chem Int Ed Engl. 2025 Dec8;64(50):e202516635. doi: 10.1002/anie.202516635. Epub 2025 Oct 12. PMID: 41077847. *Electron Microscopy and Macromolecular Crystallography Platforms*

A basic framework to explain splice-site choice in eukaryotes.

Dent CI, Prodic S, Balakrishnan A, Chhabra A, Georges JDG, Mukherjee S, Coutts J, Gitonobel M, Sarwade RD, Rosenbluh J, D'Amato M, Das PP, Guo YL, Fournier-Level A, Burke R, Sureshkumar S, Powell D, Balasubramanian S. Nat Commun. 2025 Sep 29;16(1):8284. doi: 10.1038/s41467-025-63622-9. PMID: 41022769; PMCID: PMC12480690. *Gastrointestinal Genetics Lab*

Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis.

Martínez García de la Torre RA, Vallverdú J, Xu Z, Ariño S, Ferrer-Lorente R_Zanatto L, Mercado-Gómez M, Aguilar-Bravo B, Ruiz-Blázquez P, Fernandez- Fernandez M, Navarro-Gascon A, Blasco-Roset A, Sánchez-Fernández-de-Landa P, Pera J, Romero-Moya D, Ayuso Garcia P, Martínez Sánchez C, Sererols Viñas L, Cantallops Vilà P, Cárcamo Giráldez CI, McQuillin A, Morgan MY, Moya-Rull D, Montserrat N, Eberlé D, Staels B, Antoine B, Azkargorta M, Lozano JJ, Martínez-Chantar ML, Giorgetti A, Elortza F, Planavila A, Varela-Rey M, Woodhoo A, Zorzano A, Graupera I, Moles A, Coll M, Affo S, Sancho-Bru P. Nat Commun. 2025 Feb 10;16(1):1489. doi: 10.1038/s41467-025-56024-4. PMID: 39929812; PMCID: PMC1181106210.1038/s41467-024-48763-7. PMID: 38830848; PMCID: PMC11148148. *Liver Disease Lab & Proteomics Platform*

Connectivity of the adult human brain with sequential neurogenesis of circuits and transcriptomics signatures.

Diez I, García-Moreno F, Carral-Sainz N, Stramaglia S, Nieto-Reyes A, D'Amato M, Cortes JM, Bonifazi P. Nat Commun. 2025 Dec 31;17(1):1035. doi: 10.1038/s41467-025-67785-3. PMID: 41476060; PMCID: PMC12847928. *Gastrointestinal Genetics Lab*



Synthesis, Conformal Analysis, and Antibody Binding of Staphylococcus aureus Capsular Polysaccharide Type 5 Oligosaccharides.

Østerlid KE, Li S, Unione L, Bino LD, Sorieul C, Carboni F, Berni F, Bertuzzi S, van Puffelen B, Arda A, Overkleeft HS, van der Marel GA, Romano MR, Jiménez-Barbero J, Adamo R, Codée JDC. Angew Chem Int Ed Engl. 2025 Sep 22;64(39):e202511378. doi: 10.1002/anie.202511378. Epub 2025 Aug 18. PMID: 40823959; PMCID: PMC12455396. *Chemical Glycobiology Lab*




Structural Insight Into a Human H Ferritin@Gold-Monocarbene Adduct: Auophilicity Revealed in a Biological Context.

Cosottini L, Giachetti A, Guerri A, Martinez-Castillo A, Geri A, Zineddu S, Abrescia NGA, Messori L, Turano P, Rosato A. Angew Chem Int Ed Engl. 2025 Jul 21;64(30):e202503778. doi: 10.1002/anie.202503778. Epub 2025 Apr 27. PMID: 40249912; PMCID: PMC12281091. *Structure & Cell Biology of Viruses Lab*




NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway.

Zapata-Pavas LE, Serrano-Macia M, Merlos Rodrigo MÁ, Barrenechea-Barrenechea JA, Peña-SanFelix P, Del Río-Álvarez Á, Gil-Pitarch C, Rejano-Gordillo CM, Goikoetxea-Usandizaga N, González-Recio I, Michalkova H, Mercado-Gómez M, Lachiondo-Ortega S, Castañeda A, Asensio M, Murti A, Lelou E, Nogueiras R, Mayor U, Heger Z, Sancho-Bru P, Delgado TC, Calvisi DF, Xirodimas DP, Wang B, Marin JGG, Fernandez-Barrena MG, Armengol C, Ávila M, Martínez-Chantar ML. Hepatology. 2025 Nov 14. doi: 10.1097/HEP.0000000000001614. Epub ahead of print. PMID: 41236496. *Liver Disease Lab*



Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk.

Olaizola P, Olaizola I, Fernandez de Ara M, Lapitz A, Val B, Izquierdo-Sanchez L, Fernandez-Barrena MG, Alvarez L, O'Rourke CJ, Lee-Law PY, Davies K, Gradinaru A, Jimenez-Agüero R, La Casta A, Riaño I, Macias RIR, Marin JJG, Martinez-Chantar ML, Avila MA, Aspichueta P, Andersen JB, Boulter L, Bujanda L, Rodrigues PM, Perugorria MJ, Banales JM. Hepatology. 2025 Dec 1;82(6):1461-1479. doi: 10.1097/HEP.0000000000001259. Epub 2025 Feb 11. PMID: 39932259; PMCID: PMC12614379. *Liver Disease Lab*




Mitochondrial antiviral signaling protein enhances MASLD progression through the ERK/TNF α /NF κ B pathway.

Nóvoa E, da Silva Lima N, Gonzalez-Rellan MJ, Chantada-Vazquez MDP, Verheij J, Rodriguez A, Esquinas-Roman EM, Fondevila MF, Koning M, Fernandez U, Cabaleiro A, Parracho T, Iglesias-Moure J, Seoane S, Porteiro B, Escudero A, Senra A, Perez-Fernandez R, López M, Fidalgo M, Guallar D, Martinez-Chantar ML, Dieguez C, Varela-Rey M, Prevot V, Schwaninger M, Meijnikman A, Bravo SB, Frühbeck G, Nogueiras R. Hepatology. 2025 May 1;81(5):1535-1552. doi: 10.1097/HEP.0000000000000930. Epub 2024 May 16. PMID: 38761407; PMCID: PMC11999095. *Liver Disease Lab*




Controlled Self-Immolative Release of β -Lapachone via an Optimized para-Hydroxybenzyl Linker for Targeted Pancreatic Cancer Therapy.

Becher JB, Dutta N, Navo CD, Dunsmore L, Misteli R, Gil de Montes E, Simpson GG, Alewine CC, Jiménez-Osés G, Bernardes GJL. J Am Chem Soc. 2025 Dec 31;147(52):48271-48289. doi: 10.1021/jacs.5c17598. Epub 2025 Dec 14. PMID: 41392458; PMCID: PMC12766730. *Computational Chemistry Lab*




Vesicular Rps6 Released by Astrocytes in an Experimental Model of AD Regulates Local Translation and Enhances Synaptic Integrity in Neurones.

Gamarra M, Cruz-Gambra A, Blanco-Urrejola M, González E, Azkargorta M, Elortza F, Falcón-Pérez JM, Baleriola J. J Extracell Vesicles. 2025 Dec;14(12):e70216. doi: 10.1002/jev2.70216. PMID: 41416952; PMCID: PMC12716141. *Exosomes Lab & Proteomics Platform*




Metabolic Profiling of Brain Tissue and Brain-Derived Extracellular Vesicles in Alzheimer's Disease.

Hernandez P, Rackles E, Alboniga OE, Martínez-Lage P, Camacho EN, Onaindia A, Fernandez M, Talamillo A, Falcon-Perez JM. J Extracell Vesicles. 2025 Feb;14(2):e70043. doi: 10.1002/jev2.70043. PMID: 39901643; PMCID: PMC11791017. *Exosomes Lab*




A Machine-Learning Approach Identifies Rejuvenating Interventions in the Human Brain.

Santamaria G, Iglesias C, Jung S, Arcos Hodar J, Nogueiras R, Del Sol A. Adv Sci (Weinh). 2025 Oct;12(37):e03344. doi: 10.1002/advs.202503344. Epub 2025 Jul 14. PMID: 40660726; PMCID: PMC12499397. *Computational Biology Lab*




Bis-CF₃-bipyridine Ligands for the Iridium-Catalyzed Borylation of N-Methylamides.

Marcos-Atanes D, Jiménez-Osés G, Mascareñas JL. ACS Catal. 2025 Apr 16;15(9):7112-7120. doi: 10.1021/acscatal.5c00933. PMID: 40463519; PMCID: PMC12128192. *Computational Chemistry Lab*



Impact of loosensins on the enzymatic preparation of cellulose nanocrystals.

Jabalera Y, Dahiya D, Cencerrado CDO, Caballero AJ, Zaldúa N, Eceiza A, Master ER, Perez-Jimenez R. Carbohydr Polym. 2025 Jun 1;357:123469. doi:10.1016/j.carbpol.2025.123469. Epub 2025 Mar 3. PMID: 40158993. *Synthetic Biology Lab*




Metabolic dysfunction-associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy.

Cardoso Delgado T, Martín-Cuevas C, Sánchez Hidalgo AC, Gil Gómez A, Rejano Gordillo CM, Landa J, Gallego Durán R, Goikotxea-Usandizaga N, González-Recio I, Gil-Pitarch C, Zapata-Pavas LE, Barrenechea-Barrenechea JA, Conter C, Martínez-Cruz LA, Ramos Herrero VD, Nogueiras R, Azkargorta M, Elortza F, Moncho-Amor V, Crespo J, Matheu A, Romero Gómez M, Crespo-Facorro B, Martínez- Chantar ML. Sci Adv. 2025 Oct 24;11(43):eady9758. doi: 10.1126/sciadv.ady9758. Epub 2025 Oct 22. PMID: 41124271; PMCID: PMC12542958. *Liver Disease Lab & Proteomics Platform*



Functional Variation in Human CAZyme Genes in Relation to the Efficacy of a Carbohydrate-Restricted Diet in IBS Patients.

Zamfir-Taranu A, Löscher BS, Carbone F, Hoter A, Esteban Blanco C, Bozzarelli I, Torices L, Routhiaux K, Van den Houte K, Bonfiglio F, Mayr G, Corsetti M, Naim HY, Franke A, Tack J, D'Amato M. Clin Gastroenterol Hepatol. 2025 Jun;23(7):1228-1237.e10. doi: 10.1016/j.cgh.2024.09.004. Epub 2024 Oct 14. PMID: 39413891. *Gastrointestinal Genetics Lab*




Fructose-induced progression of steatohepatitis involves disrupting aldolase B-AMPK signaling in methionine adenosyltransferase 1A deficient mice.

Barbier-Torres L, Luque-Urbano M, Chhimwal J, Robinson AE, Fernández-Ramos D, Lopitz-Otsoa F, Van Eyk JE, Millet O, Mato JM, Lu SC. Metabolism. 2025 Apr;165:156154. doi: 10.1016/j.metabol.2025.156154. Epub 2025 Feb 6. PMID: 39922455; PMCID: PMC12036799. *Precision Medicine and Metabolism Lab*



Organic Carbon Monoxide Prodrugs Activated by Endogenous Reactive Oxygen Species for Targeted Delivery.

Cernauskiene I, Navo CD, Labão-Almeida C, J Proctor RS, Gless BH, Khaw WT, Tang C, Muriel-Olaya MM, Jiménez-Osés G, Bernardes GJL. J Am Chem Soc. 2025 Jul 16;147(28):24691-24698. doi: 10.1021/jacs.5c05952. Epub 2025 Jul 3. PMID: 40611362; PMCID: PMC12272688. *Computational Chemistry Lab*




Computation of Protein Thermostability and Epistasis.

Peccati F., Segovia C.M., Núñez-Franco R., Jiménez-Osés G.
Wiley Interdisciplinary Reviews: Computational Molecular Science, 15 (5), art. no. e70045DOI: 10.1002/wcms.70045.
Computational Chemistry Lab



Friends to remember innate immune memory regulation by the microbiota.

Pellon A, Palacios A, Abecia L, Rodríguez H, Anguita J.
Trends Microbiol. 2025 May;33(5):510-520. doi: 10.1016/j.tim.2024.12.002. Epub 2025 Jan 9. PMID: 39794207. .
Inflammation and Macrophage Plasticity Lab



Roadblocks of Urinary EV Biomarkers: Moving Toward the Clinic.

Droste M, Puhka M, van Royen ME, Ng MSY, Blijdorp C, Alvarez-Llamas G, Borràs FE, Büscher AK, Bussolati B, Dear JW, Falcón-Pérez JM, Giebel B, Grange C, Hoorn EJ, Leivo J, Lenassi M, Llorente A, Lucien F, Mertens I, Mischak H, Pink D, Tertel T, Tiwari S, Di Vizio D, Yuen PST, Zarovni N, Jenster G, Burger D, Martens-Uzunova ES, Erdbrügger U. J Extracell Vesicles. 2025 Jul;14(7):e70120. doi: 10.1002/jev2.70120. PMID: 40673839; PMCID: PMC12269535 *Exosomes Lab*



BMC Series

BMC Veterinary Research

Joaquín Castilla
Advisory Board

BMC Biophysics

Óscar Millet
Associate Editor



Maria Vivanco
Editor Board



Arkaitz Carracedo
Consultant Editor



Malu Martínez-Chantar
Associate Editor



Ana Ruiz-Sáenz
Review Editor



Joaquín Castilla
Associate Editor



Rosa Barrio
Associate Editor



Gonzalo Jiménez-Osés
Review Editor



Ana Ruiz-Sáenz
Review Editor



Juan Manuel Falcón
Review Editor



ELSEVIER



Félix Elortza
Editor Board



Rosa Barrio



Associate Editor



Review Editor



Review Editor

In Cellular Stress and Survival: Crosslinks, Intersections, and Pathways



PLOS ONE
Editorial Board

Antonio Del Sol
Editor Board
Óscar Millet
Editor Board



Malu Martínez-Chantar
Associate Editor



AMERICAN
SOCIETY FOR
MICROBIOLOGY

Infection and
Immunity

Juan Anguita
Editor Board




Jesús Jiménez-Barbero
Senior Editor



Jesús Jiménez-Barbero
Advisory Board



Jesús Jiménez-Barbero
Advisory Board



Rosa Barrio
Editor Board

Juan Anguita
Senior Editor

Óscar Millet
Editor Board



Maria Vivanco
Editor Board



Eduardo Berra
Associate Editor



Juan Manuel Falcón
Deputy Editor



Juan Manuel Falcón
Associate Editor



Jesús Jiménez-Barbero
Advisory Board



Jesús Jiménez-Barbero
Advisory Board




Óscar Millet
Editor Board

Editorial & Advisory Boards



Óscar Millet
Editor Board




Malu Martínez-Chantar
Editor Board
Juan Manuel Falcón
Associate Editor



Malu Martínez-Chantar
Editor Board


PhD Thesis Covers




María Reyes
Luque
28/03/2025




Alexandre
Bosch
04/04/2025




Izaro
Kortazar
14/04/2025



Jon
Corres
30/04/2025



Roberto
Fuentes
15/05/2025




Adrián
Gaite
15/05/2025

PhD Thesis Covers




**Ricardo
Escarín**

30/05/2025



**Clara
García Vallicrosa**

10/06/2025




**Ibon
Martínez**

19/04/2024




**Ander Blas
Martín**

15/07/2025



**Tania
Pereira**

05/09/2025




**Maider
Fagoaga**

12/09/2025



**Marta
Pardo**

13/10/2025



**Jone R
Crespo**

03/11/2025




**Maddi
Oyangueren**

02/12/2025



**Andrea
Fernández**

10/12/2025



**Sara
Samperio**

16/12/2025

Projects & Funding Applications

210

Active
Projects



117

Funding
Applications

49

Awarded
Applications

Along 2025, **49 new proposals have been funded** from different organizations from the Basque Country, Spain, and other countries, while CIC bioGUNE investigators **presented 117 applications**. The overall number of **active projects** stands at **210**.



From a funding perspective, 2025 was exceptionally successful, particularly at the European level. The center secured a prestigious **ERC Synergy Grant** coordinated by **Raúl Pérez-Jiménez** (RGNcestry project on RNA-guided nucleases) and an ERC Proof of Concept Grant awarded to **Jesús Jiménez-Barbero** (BiParatopic, focused on bispecific antibodies for cancer).

In addition, CIC bioGUNE participated in the **MSCA Doctoral Network (EVADERE)** and international recognition through the **Balzan Prize** awarded to **Arkaitz Carracedo**.

At the national level, the center obtained **nine “Generación de Conocimiento” projects**, representing approximately €2.48 M plus additional predoctoral funding, alongside **strong public-private collaborations** such as CATIB and ERYSAFETY.

Regional funding through **ELKARTEK and IKUR programs**, together with competitive private and foundation support (including AECC and CaixaResearch), further diversified the funding portfolio.



Research Projets

DETAILS



Human Capital

DETAILS

International

The 32th Research Grant

**Mizutani Foundation for
Glycoscience**



June Ereño-Orbea

Cancer Glycoimmunology Lab

Leveraging Siglec glycoimmune checkpoints to boost CAR therapy efficacy

The International E. Balzan Prize Foundation



Arkaitz Carracedo

*Cancer Cell Signaling &
Metabolism Lab*

Coordinator:

BIOZENTRUM
The Center for
Molecular Life Sciences

The regulation of polyamine homeostasis in cancer.

Europe

ERC Proof of Concept



Coordinator:



BiParatopic – Bispecific bi-paratopic antibodies for the treatment of cancer

Jesús Jiménez-Barbero

Chemical Glycobiology Lab

ERC Synergy Grant



Coordinator:



RGNcestry – Tracing and harnessing the ancestry of RNA-guided nucleases

Raúl Pérez-Jiménez

Synthetic Biology Lab

MSCA Doctoral Networks



Coordinator:



EVADERE – Enhanced Vaccines DESIGN against antimicrobial Resistance

Juan Anguita

Inflammation and Macrophage Plasticity Lab

Private

IX Research Project: For a world without ALS



Raúl Pérez-Jiménez

Synthetic Biology Lab

Synthetic CRISPR systems and base editing for high-precision, unrestricted correction of ALS-associated mutations

IV Research Projects: For a World Without ALS - Young Researchers



Ylenia Jabalera

Synthetic Biology Lab

New LNP-based database editor systems for the study and correction of ALS-associated mutations

Private

XXII National Competition for Research Grants in Life and Material Sciences



FUNDACIÓN
RAMÓN ARECES



Boosting CAR therapy
efficacy with modified
glycans

June Ereño-Orbea

*Cancer Glycoimmunology
Lab*

CaixaResearch Health 2025



"la Caixa" Foundation



GlycoTARGET – Advanced
platform for targeting tumor-
associated glycans

June Ereño-Orbea

*Cancer Glycoimmunology
Lab*

"Sinergias" AECC



SMARTtherapy – antibody-
based Sensor for Monitoring
Adverse Reactions in
immunotherapy

Gabriel Ortega

*Precision Medicine and
Metabolism Lab*

Spain

Knowledge Generation Projects



9 funded projects 2.484.000 €
4 associated predoctoral contracts 536.800 €

91% Success rate

Proof of Concept Projects



4 funded projects 898.183 €

50% Success rate

Public-Private Partnership Projects



Juan Manuel Falcón
Exosomes Lab

Coordinator:



ERYSAFETY – *In vivo* research on hemolytic anemia for drug safety assessment



Urko M. Marigorta
Integrative Genomics Lab



Ana Ruiz- Sáenz
Cancer Therapy Resistance Lab

Coordinator:



CATIB – Novel CCR9 antibody for the treatment of inflammatory bowel disease

Basque Country

ELKARTEK Collaborative Fundamental Research Project



1.248.658 €

DESARROLLO DE MODELOS DE MEDICINA PERSONALIZADA PARA LA
PREDICCIÓN TEMPRANA DE ENFERMEDADES PREVALENTES E
INFECCIOSAS

Leader: **CICbioGUNE**
MEMBER OF BASQUE RESEARCH
& TECHNOLOGY ALLIANCE



bioaraba



Basque Country

Cancer Research Projects



Advanced Therapies for
Metastatic Prostate Cancer:
Bispecific Antibodies and
Nanotechnology

Marco Piva

*Cancer Cell Signaling and
Metabolism Lab*

Basic and Applied Research Projects



Unraveling prostate
progression: Longitudinal
analysis and spatial
transcriptomics to identify key
biomarkers and mechanisms in
the transition from hyperplasia
to cancer

Isabel Mendizabal

*Precision Cancer Multiomics
Lab*

Basque Country

IKUR Challenges: Neurobioscience

ikur
estrategia



ikerbasque
Basque Foundation for Science



Financiado por
la Unión Europea
NextGenerationEU

NeuCRISPR – Development of broad action CRISPR gene editors for Amyotrophic Lateral Sclerosis (ALS)



Raúl Pérez-Jiménez

Synthetic Biology Lab



Juan Manuel Falcón

Exosomes Lab

ExoPsyCog II – Brain-derived plasma extracellular vesicles as biomarkers and treatment of psychotic disorders

Spain

Ramón y Cajal Program



Luca Unione

Chemical Glycobiology Lab



Amaia Ercilla

*Cancer Cell Signaling and
Metabolism Lab*

Juan de la Cierva Program



Ana Krotenberg

Cancer Therapy Resistance Lab

Private

Research Fellow

ikerbasque
Basque Foundation for Science



Ylenia Jabalera

Synthetic Biology Lab

Exploring and designing novel programmable insertion genome editing tools through molecular evolution

Junior Leader - Retaining

 "la Caixa" Foundation



Ylenia Jabalera

Synthetic Biology Lab

Exploring and designing novel programmable insertion genome editing tools through molecular evolution

AECC Talent

 asociación española contra el cáncer



Amaia Navarro

Liver Disease Lab

Targeting epigenetic modifications in myeloid cells for therapeutic intervention in MASH-driven hepatocellular carcinoma

Predoctoral AECC

 minbiziaren aurka Bizkaian


 contra el cáncer en Bizkaia



Irati Aguirre

Cancer Cell Signaling and Metabolism Lab

Identification of molecular and phenotypic processes modulating prostate cancer persister cells to refine clinical management



Uxue Armendariz

Cancer Therapy Resistance Lab

Deciphering the impact of tumor-specific glycosylation in T-DXd efficacy in HER2-positive breast cancer

Basque Country

Training Programs for Non-Doctoral Research Staff Corresponding to 2025-2026 Academic Year



Sara Del Palacio

*Cancer Cell Signaling
and Metabolism Lab*



Candela Gerediaga

*Cancer Cell Signaling and
Metabolism Lab*



Carlos Díaz

Liver Disease Lab



3

Technology Transfer Programs

TECHNOLOGY TRANSFER PROGRAMS



3

Technology-Based
Firms (TBFs)

TBFs



4

Accreditations

ACCREDITATIONS

Innovation remained a cornerstone of CIC bioGUNE's activity. In 2025, the center reported **seven new invention disclosures**, covering areas such as cancer therapeutics, enzyme engineering, prion biology, and gene therapy strategies.

Technology transfer activities showed significant dynamism, with **43 new business leads, 59 material and 20 confidentiality agreements, and ongoing licensing and sponsorship negotiations**. These figures demonstrate the center's ability to translate scientific knowledge into tangible societal and industrial impact.

A key milestone in 2025 was the **establishment of a strategic collaboration with CIMA (University of Navarra)**, aimed at advancing innovative therapies through combined expertise in gene editing, viral vectors, and clinical development.

Importantly, CIC bioGUNE **obtained the ISO 56001:2024 certification for Innovation Management**, reinforcing its structured approach to innovation governance and continuous improvement.


Basque Tek Ventures



Artificial intelligence-accelerated design of functional proteins.



Gonzalo Jiménez-Osés



Technology Transfer Program



Washing cabinet for cages and racks (animal facility).



Juan Anguita

Framework for Collaboration Agreements in Advanced Therapies




The strategic agreement between CIC bioGUNE and CIMA-University of Navarra will boost biomedical innovation in advanced therapies, combining expertise in gene editing, viral vectors, and clinical development to offer more precise and personalized treatments.



Raúl Pérez-Jiménez



Joaquín Castilla



2016

Discovery of innovative «first-in-class» therapies, based on the principle of **pharmacological chaperones**, for the treatment of rare and ultra-rare diseases. 1 ODD (EMA & FDA). Now in Phase II in USA.



2020

Research & development of **Biomedical Projects**, **NMR, Biological & Medical Data Analytics**.



2022

Advanced Therapy, **CAR-T & Biologics (Antibody Therapy) for solid tumors**.

CONTINUE TO BE VALID

This is a translation of the certificate ES20/208566

The management system of

**ASOCIACIÓN CENTRO DE INVESTIGACIÓN
COOPERATIVA EN BIOCENCIAS – CIC
BIOGUNE**

Central: Parque Científico Tecnológico de Bizkaia, Edificio 801-A, 48160 Derio, Bizkaia

has been assessed and certified as meeting the requirements of

ISO 9001:2015

For the following activities

Metabolic analysis of biological samples by Nuclear Magnetic Resonance.

SGS

Certificado ES19/85323

El sistema de gestión de

**ASOCIACIÓN CENTRO DE INVESTIGACIÓN
COOPERATIVA EN BIOCENCIAS – CIC
BIOGUNE**

Central: Parque Científico Tecnológico de Bizkaia, Edificio 801-A, 48160 Derio, Bizkaia

ha sido evaluado y certificado que cumple con los requisitos de

ISO 56001:2024

Para las siguientes actividades

El diseño y realización de proyectos de Investigación para el descubrimiento de nuevos fármacos y de nuevos biomarcadores que resulten útiles en el diagnóstico y pronóstico de enfermedades.

SGS

This is a translation of the certificate ES23/00000929

The management system of

**ASOCIACIÓN CENTRO DE INVESTIGACIÓN
COOPERATIVA EN BIOCENCIAS – CIC
BIOGUNE**

Parque Científico Tecnológico de Bizkaia, Edificio 801-A, 48160 Derio, Bizkaia

has been assessed and certified as meeting the requirements of

ISO 9001:2015

For the following activities

Provision of quality control service of samples using electron microscopy.

SGS



The new standard has been obtained:

ISO 56.001:2024

Innovation Management System

(certificate issuance pending)

- The institute also strengthened its human capital through the recruitment of highly competitive researchers via Ramón y Cajal, Juan de la Cierva, AECC Talento, La Caixa Junior Leader programs.
- New group leaders and fellows reinforced strategic areas including cancer biology, glycobiology, synthetic biology, and metabolic disease, ensuring sustained leadership in key biomedical domains and long-term scientific renewal.
- **A new research group**, “Precision Cancer Multiomics Lab” was created, led by Dr. Isabel Mendizabal



Isabel Mendizabal

*Precision Cancer
Multiomics Lab*



**AVADHESHA
SUROLIA AWARD**



Dr. Jesús Jiménez-Barbero, Scientific Director and Group Leader of the Chemical Glycobiology Lab, receives the **Avadhesha Surolia Award** for excellence in Glycobiology from Indian Institute of Science Alumni Association (IIScAA) and Indian Institute of Science (IISc).



**RESEARCH
EXCELLENCE AWARD**



Dr. Óscar Millet, Principal Investigator of the Precision Medicine and Metabolism Lab, has been honored with the **2025 Research Excellence Award** granted by the Royal Spanish Society of Chemistry (RSEQ) in recognition of his outstanding scientific career.



**NATIONAL AWARD
FOR EMERGING
RESEARCH LEADERS**



Dr. June Ereño-Orbea, Ikerbasque researcher, Caixa Junior Leader and leader of the Cancer Glycoimmunology Lab, has been awarded the **National Award from the Specialized Group of Biological Chemistry of the RSEQ for Emerging Research Leaders**, in its sixth edition.



Media
Impact

184

Our noteworthy discoveries and outcomes of **2025** have received considerable attention across general and specialized printed magazines, online platforms, television, and radio programs, enhancing the broad interest and coverage of our scientific advancements.



People
Reached
by Citizen
Participation
Actions

32 k

CIC bioGUNE reinforces its commitment to society:

- Engaging a diverse audience through radio, by the “BioEnredados: Uniendo ciencia y Vida” **podcast**, and digital platforms to communicate project outcomes captivantly.
- **Science outreach fairs** further emphasize interactive presentations of the research findings to the public.
- The innovative fusion of **science and art** underscores the center’s dedication to fostering creativity and disseminating scientific results.
- **Cancer Talks “Hablemos de Cáncer”** initiative, which fosters open dialogue between researchers, patients, clinicians, and the public.





Crowdfunding

Collaborative efforts with charitable organizations aim to bring science to the public and advocate for the importance of research investment in community development. Notable initiatives include charity runs and benevolent events organized by local associations to raise funds for different research groups at CIC bioGUNE.



Equality Plan Renewal: 2024- 2027

CICbiGUNE & PROSPER TIKER						
UNDER NEGOTIATION						
FASES	ACCIONES	4Q24	1Q25	2Q25	3Q25	4Q25
F1. Ajuste Metodológico y Presentación	Acción 1. Reunión de apertura de proceso					
	Acción 2. Constitución Comisión negociadora					
	Acción 3. Planteamiento de trabajo con la Comisión Negociadora del proceso					
	Acción 4. Primera reunión con la Comisión de Igualdad					
F2. Elaboración de Diagnóstico	Acción 5. Análisis de fuentes disponibles y contraste					
	Acción 6. Actualización del protocolo frente al acoso sexual y por razón de sexo					
	Acción 7. Encuesta a la plantilla					
	Acción 8. Análisis de información, contrastes y diseño borrador diagnóstico					
	Acción 9. Sensibilización en igualdad					
	Acción 10. Segunda reunión con Comisión de Igualdad					
F3. Diseño del Plan	Acción 11. Elaboración del diagnóstico final					
	Acción 12. Contraste y ajuste de las medidas del Plan					
F4. Presentación de resultados y registro	Acción 13. Diseño de borrador de Plan de igualdad					
	Acción 14. Redacción final del Plan de igualdad					
	Acción 15. Tercera reunión con Comisión de igualdad					
	Acción 16. Registro y comunicación de los resultados a la plantilla					

Regulatory Update

January 2025 –Adaptation Protocol for the management and investigation of conflicts, workplace harassment, sexual harassment, harassment based on sex, sexual orientation and identity and gender expression, violence in the workplace and antisocial behavior

Royal Decree 1026/2024 which develops the planned set of measures for equality and non-discrimination of **LGBTI people** in companies.

Annual Activities

February 11th



March 8th



November 25th

